B cell checkpoints in autoimmune rheumatic diseases

被引:68
|
作者
Rubin, Samuel J. S. [1 ,2 ,3 ]
Bloom, Michelle S. [1 ,2 ,3 ]
Robinson, William H. [1 ,2 ,3 ]
机构
[1] Stanford Univ, Sch Med, Immunol Program, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Med, Sch Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA
[3] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; FC-GAMMA RECEPTOR; T-CELL; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; IMMUNE-COMPLEX; PLASMA-CELLS; IN-VITRO; ANTIGEN RECEPTOR; ANKYLOSING-SPONDYLITIS;
D O I
10.1038/s41584-019-0211-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen-presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co-engagement engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases.
引用
收藏
页码:303 / 315
页数:13
相关论文
共 50 条
  • [1] B cell checkpoints in autoimmune rheumatic diseases
    Samuel J. S. Rubin
    Michelle S. Bloom
    William H. Robinson
    [J]. Nature Reviews Rheumatology, 2019, 15 : 303 - 315
  • [2] Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases
    Gerasimova, Elena V.
    Tabakov, Dmitry V.
    Gerasimova, Daria A.
    Popkova, Tatiana V.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [3] B cell depletion in autoimmune rheumatic diseases
    Pitashny, M
    Shoenfeld, Y
    [J]. AUTOIMMUNITY REVIEWS, 2005, 4 (07) : 436 - 441
  • [4] Checkpoints controlling the induction of B cell mediated autoimmunity in human autoimmune diseases
    Reijm, S.
    Kissel, T.
    Toes, R. E. M.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2020, 50 (12) : 1885 - 1894
  • [5] Cell therapy in rheumatic Autoimmune diseases
    Hiepe, F.
    [J]. ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 : S14 - S15
  • [6] Stem cell transplantation for rheumatic autoimmune diseases
    Huegle, Thomas
    van Laar, Jacob M.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2008, 10 (05)
  • [7] Stem cell transplantation for rheumatic autoimmune diseases
    Thomas Hügle
    Jacob M van Laar
    [J]. Arthritis Research & Therapy, 10
  • [8] Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies
    Meffre, Eric
    O'Connor, Kevin C.
    [J]. IMMUNOLOGICAL REVIEWS, 2019, 292 (01) : 90 - 101
  • [9] Autoimmune Rheumatic Diseases 1 Clinical aspects of autoimmune rheumatic diseases
    Goldblatt, Fiona
    O'Neill, Sean G.
    [J]. LANCET, 2013, 382 (9894): : 797 - 808
  • [10] Methylation of T and B Lymphocytes in Autoimmune Rheumatic Diseases
    Deng, Tiantian
    Wang, Zihan
    Geng, Qishun
    Wang, Zhaoran
    Jiao, Yi
    Diao, Wenya
    Xu, Jiahe
    Deng, Tingting
    Luo, Jing
    Tao, Qingwen
    Xiao, Cheng
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2024, 66 (03) : 401 - 422